0001562180-24-005516.txt : 20240702 0001562180-24-005516.hdr.sgml : 20240702 20240702163137 ACCESSION NUMBER: 0001562180-24-005516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240628 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ostrowski Erik CENTRAL INDEX KEY: 0001762507 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 241096063 MAIL ADDRESS: STREET 1: C/O AVROBIO, INC. STREET 2: ONE KENDALL SQUARE, BLDG. 300, #201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-06-28 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001762507 Ostrowski Erik C/O AKEBIA THERAPEUTICS, INC 245 FIRST ST. CAMBRIDGE MA 02142 false true false false SVP, CFO, CBO & Treasurer false Common Stock 2024-06-28 4 A false 350000.00 0.00 A 350000.00 D Stock Option (Right to buy) 1.02 2024-06-28 4 A false 500000.00 0.00 A 2034-06-28 Common Stock 500000.00 500000.00 D The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the RSUs will vest upon each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer on each vesting date. The options were granted by the Issuer as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each vesting date. /s/Carolyn Rucci, attorney-in-fact for Erik Ostrowski 2024-07-02